PROGLIO

High-grade Glial Tumors Therapeutic Follow-up

The investigation of blood biomarkers for high-grade glial tumors remains a major challenge in order to predict and monitor treatment response. Identify an accurate circulating biomarker is a highly rewarding area of interest in neuro-oncology.

​

PROGLIO is a pilot French, prospective, observational, monocentric study with longitudinal follow-up, in which 30 patients with high grade brain tumors are included. Blood samples will be taken during their treatment follow-up to evaluate plasma concentrations of hPG80.

​​

Study in partnership with the Centre Jean Perrin of Clermond-Ferrand (France).

​

PROGLIO is registered at ClinicalTrials.gov (NCT05157594)

​

Current Status: Follow-up

​​